Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in uterine (endometrial) cancer
- Trial result
Uterine (endometrial) cancer
Pembrolizumab monotherapy is associated with longer time to next treatment than chemotherapy in a real-world dMMR endometrial cancer study
Pembrolizumab is an anti–PD-1 monoclonal antibody tested here as first-line (1L) chemotherapy-free monotherapy in a US Flatiron real-world retrospective cohort of dMMR/MSI-H advanced or recurrent endometrial cancer…
- Trial result
Uterine (endometrial) cancer
E7386 (β-catenin–CBP inhibitor) + lenvatinib delivers 36.7% ORR in post–chemo/PD-(L)1 advanced endometrial cancer
E7386 is an oral inhibitor of the beta-catenin/CBP interaction, combined with the multikinase VEGFR/FGFR inhibitor lenvatinib in the global Phase 1b/2 Study 102 dose-expansion cohort (NCT04008797). All 30 patients…
NCT04008797 - New trial
Uterine (endometrial) cancer
Early Phase 1 tirzepatide dual GIP/GLP-1 receptor agonist + LNG-IUD progestin in EIN/grade 1 endometrioid EC
This single-arm, window-of-opportunity pilot at Milton S. Hershey Medical Center evaluates feasibility, safety, and preliminary efficacy of adding tirzepatide (Eli Lilly’s dual GIP and GLP-1 receptor agonist that…
NCT07812636 Exploratory - New trial
Uterine (endometrial) cancer
Phase 2 semaglutide GLP-1 receptor agonist + LNG-IUD progestin for fertility-sparing endometrial neoplasia
This Phase 2, single-arm conservative-management study tests whether combining a levonorgestrel-releasing IUD (local progestin that activates the progesterone receptor in the endometrium), semaglutide 2.4 mg (Novo…
NCT07820358 Exploratory - Trial result Spotlight
Uterine (endometrial) cancer
Ribociclib (CDK4/6) + everolimus (mTOR) + letrozole (aromatase) lifts ORR only in endocrine-pretreated recurrent endometrial cancer
Everolimus (oral mTORC1 inhibitor) plus letrozole (aromatase inhibitor) was tested with vs without ribociclib (CDK4/6 inhibitor) in a randomized Phase 2 recurrent endometrial cancer trial (NCT03008408). In the…
NCT03008408 - New trial
Uterine (endometrial) cancer
Phase 2 OK-1 (SHetA2) Grp78/Hsc70/mortalin inhibitor plus weekly paclitaxel in recurrent endometrial cancer
This single-arm Phase 2 study with a safety lead-in tests whether adding OK-1 to weekly paclitaxel can reduce tumor burden in patients with measurable advanced or recurrent endometrial cancer after prior…
NCT07737795 Exploratory - Trial result
Uterine (endometrial) cancer
Cediranib (VEGFR TKI) + weekly paclitaxel lifts early disease control/ORR in platinum-pretreated endometrial cancer—but benefit washes out by 6 months
Cediranib is an oral VEGFR1-3–targeting anti-angiogenic TKI; in COPELIA (UK multicentre, open-label, randomized Phase 2; NCT03570437), patients with advanced/recurrent endometrial cancer after ≥1 prior platinum…
NCT03570437 - Trial result
Uterine (endometrial) cancer
Niraparib (PARP inhibitor) + dostarlimab (PD-1) maintenance cuts PFS risk ~40% in advanced/recurrent endometrial cancer—at major toxicity cost, no OS gain
Niraparib is an oral PARP inhibitor added to dostarlimab (anti–PD-1) maintenance after induction dostarlimab + carboplatin/paclitaxel in Part 2 of the Phase 3 ENGOT-EN6-NSGO/GOG-3031/RUBY trial (NCT03981796). In…
NCT03981796 - Trial result Spotlight
Uterine (endometrial) cancer
Puxitatug Samrotecan B7-H4 ADC Posts 48% ORR in Relapsed Endometrial Cancer
Puxitatug samrotecan (AZD8205) is a B7-H4–directed topoisomerase I ADC tested in the Phase 1/2a BLUESTAR expansion (NCT05123482) in B7-H4-positive relapsed/metastatic endometrial or ovarian cancer after…
NCT05123482 - Trial result
Uterine (endometrial) cancer
Atezolizumab (PD-L1) + bevacizumab (VEGF) posts 33.9% ORR in platinum-pretreated recurrent/metastatic endometrial cancer
Atezolizumab is an anti–PD-L1 immune checkpoint inhibitor and bevacizumab is an anti-VEGF monoclonal antibody; this Phase 2 open-label, multicenter, single-arm study treated ICI-naïve recurrent/metastatic endometrial…
NCT03526432 - Trial result
Uterine (endometrial) cancer
Dostarlimab (PD-1) + carboplatin/paclitaxel shows 57.9% 4-year PFS and ~54% “cure fraction” in dMMR/MSI-H endometrial cancer (RUBY)
Dostarlimab (Jemperli) is an anti–PD-1 monoclonal antibody combined with carboplatin–paclitaxel (CP) as first-line therapy for primary advanced or recurrent dMMR/MSI-H endometrial cancer in the Phase 3, randomized…
NCT03981796 - Trial result
Uterine (endometrial) cancer
Pembrolizumab (PD-1) + carboplatin/paclitaxel sustains 48-mo OS gains in dMMR endometrial cancer
Pembrolizumab is an anti–PD-1 checkpoint inhibitor added to carboplatin/paclitaxel (CP) induction (6 cycles Q3W) followed by pembrolizumab maintenance (Q6W up to 24 months) in the Phase 3, randomized…
NCT03914612 - Trial result
Uterine (endometrial) cancer
Dostarlimab (PD-1) + Pelvic IMRT in MMR-D Endometrial Cancer: ctDNA Clears in Most, Flags Distant Relapse
D-RT (NCT04774419) is an investigator-initiated, single-arm Phase II study testing adjuvant dostarlimab (anti–PD-1 checkpoint inhibitor) given concurrently with standard pelvic IMRT after surgery in newly diagnosed…
NCT04774419 - New trial Spotlight
Uterine (endometrial) cancer
Phase 3 PF-08634404 PD-1×VEGF bispecific antibody plus chemo vs pembrolizumab in pMMR endometrial cancer
Pfizer’s Symbiotic-GYN-18 (NCT07578649) is a Phase 3, open-label, randomized study testing whether PF-08634404—an investigational PD-1 and VEGF–targeted bispecific antibody—combined with standard chemotherapy…
NCT07578649 Registrational - New trial
Uterine (endometrial) cancer
Phase 2 elacestrant oral SERD (estrogen receptor degrader) + everolimus mTOR inhibitor in ER+ endometrial cancer
This Phase 2, single-arm interventional study (ELAVERA) at UCLA/Jonsson Comprehensive Cancer Center evaluates elacestrant (an oral selective estrogen receptor degrader that binds ER and promotes receptor degradation)…
NCT07634601 Exploratory - New trial
Uterine (endometrial) cancer
Phase 1/2 MR‑guided adaptive IMRT (MR‑linac–based pelvic radiation) after surgery in high‑risk endometrial cancer
Rutgers Cancer Institute of New Jersey (Rutgers University) is running this Phase 1/2 feasibility study to test whether daily MRI‑guided, online adaptive pelvic IMRT can be delivered safely and consistently as…
NCT07643012 Exploratory - Trial result
Uterine (endometrial) cancer
Lenvatinib (VEGFR/FGFR TKI) + pembrolizumab (PD-1) improves OS/PFS after (neo)adjuvant platinum in endometrial cancer
Lenvatinib is an oral multi-kinase antiangiogenic TKI (VEGFR1–3/FGFR1–4, etc.) combined with pembrolizumab, a PD-1 inhibitor, and was analyzed in two Phase 3 randomized trials restricted to patients whose only prior…
- New trial
Uterine (endometrial) cancer
Phase 2 pembrolizumab PD-1 inhibitor + lenvatinib multi-kinase (VEGFR/FGFR) inhibitor in pMMR endometrial cancer.
This Phase 2, open-label, single-arm study at the University of Miami evaluates pembrolizumab (Merck/MSD; PD-1–blocking monoclonal antibody that restores T-cell anti-tumor activity) combined with lenvatinib (Eisai;…
NCT07594015 Exploratory - New trial
Uterine (endometrial) cancer
Phase 3 Signatera ctDNA MRD assay (tumor-informed personalized ctDNA tracking) vs vaginal brachytherapy in early endometrial cancer.
This Phase 3, randomized, multicenter study tests whether a ctDNA-guided “de-escalation” strategy after surgery is safe in Stage I high-intermediate risk endometrial cancer. Natera sponsors the trial using its…
NCT07339384 Exploratory - New trial
Uterine (endometrial) cancer
Phase II enfortumab vedotin (nectin-4 ADC) in recurrent/persistent endometrial carcinoma post-IO
Open-label testing of EV in a post-progression setting, including after pembrolizumab-based regimens, where options are often limited to chemo or lenvatinib+pembro backbones. EV’s success in urothelial cancer plus…
NCT07139977 Exploratory - Trial result Spotlight
Uterine (endometrial) cancer
PARP Inhibitor Rucaparib Extends PFS to 28 mo in Metastatic/Recurrent Endometrial Cancer
Rucaparib, an oral PARP1/2 inhibitor that exploits tumor DNA-repair defects, was tested as switch-maintenance after 1–2 chemotherapy lines in a double-blind Phase II trial (NCT03617679). Seventy-nine patients with…
NCT03617679 - New trial
Uterine (endometrial) cancer
Phase 1b Tirzepatide Study: Targets insulin, fat metabolism, and mTOR signaling.
In this randomized trial by UNC Lineberger Comprehensive Cancer Center, women with obesity, in situ, or Grade 1 endometrial cancer receive either 4 weeks of tirzepatide or no tirzepatide prior to surgery. Tirzepatide…
NCT07078838 Exploratory - New trial
Uterine (endometrial) cancer
Phase 1 Pre-Operative Tirzepatide Study: Dual GIP/GLP-1 receptor agonist in obesity-driven endometrial cancer
This Phase 1 window study at UNC Lineberger Comprehensive Cancer Center evaluates tirzepatide’s potential to improve metabolic milieu and disrupt tumor biology in obese women with early-stage endometrial carcinoma.…
NCT07065552 Exploratory - Trial result Spotlight
Uterine (endometrial) cancer
Rinatabart Sesutecan FRα-ADC Yields ~50% ORR After PD-1/Platinum Failure in Advanced Endometrial Cancer
Rinatabart sesutecan is a folate-receptor-α–targeted antibody-drug conjugate linked to the exatecan topoisomerase-I payload. In the GTC1184-01 phase 1/2 expansion (NCT05579366), 64 heavily pre-treated metastatic…
NCT05579366 - Trial result
Uterine (endometrial) cancer
Dostarlimab + Carbo/Taxol Delays Next Therapy by 11 mo in Front-Line Advanced Endometrial Cancer
Dostarlimab, an anti-PD-1 antibody was combined with carboplatin–paclitaxel (C/P) in the phase 3 RUBY trial (NCT03981796) for 494 patients with advanced or recurrent endometrial cancer (pA/rEC). Compared to placebo +…
NCT03981796 - New trial
Uterine (endometrial) cancer
Phase 3 Sacituzumab Tirumotecan TROP2-directed ADC for Endometrial Cancer
This Phase 3 study evaluates whether sacituzumab tirumotecan combined with pembrolizumab prolongs survival and delays disease progression versus pembrolizumab alone in patients with advanced or recurrent mismatch…
NCT06952504 Registrational - Trial result
Uterine (endometrial) cancer
Dostarlimab + carboplatin/paclitaxel stretches time to next therapy by ≥5 months in frontline advanced endometrial cancer
Dostarlimab, an anti-PD-1 antibody, was paired with standard carboplatin (AUC 5)–paclitaxel (175 mg/m²) for six cycles then continued as Q6-week maintenance in the phase 3 RUBY trial (ENGOT-EN6-NSGO/GOG-3031;…
NCT03981796 - New trial
Uterine (endometrial) cancer
Phase III T-DXd, a HER2-directed ADC with topoisomerase I inhibition in advanced endometrial cancer
This randomized controlled trial evaluates first-line treatment in advanced or recurrent HER2-expressing endometrial cancer. Patients receive T-DXd with rilvegostomig or pembrolizumab versus standard chemotherapy…
NCT06989112 - Trial result
Uterine (endometrial) cancer
Lynch-like MSI-H Endometrial Cancer Exhibits Superior Outcomes with Pembrolizumab
In this phase 2 trial of recurrent platinum-resistant MSI-H/dMMR endometrial cancer patients fully sequenced via whole exome and FoundationOne, the Lynch-like subgroup achieved a 100% objective response rate compared…
- New trial
Uterine (endometrial) cancer
RESOLVE Trial Evaluates Multi-Agent Targeted Combinations in Recurrent ER+ Endometrial and Ovarian Cancer
Dana-Farber Cancer Institute is leading a multi-cohort phase II study assessing different targeted regimens—combining letrozole with abemaciclib alone or with LY3023414, metformin, or zotatifin—in patients with…
NCT03675893
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.